Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact

Archive ouverte

Houvenaeghel, Gilles | de Nonneville, Alexandre | Cohen, Monique | Classe, Jean-Marc | Reyal, Fabien | Mazouni, Chafika | Chopin, Nicolas | Martinez, Alejandra | Daraï, Emile | Coutant, Charles | Colombo, Pierre-Emmanuel | Gimbergues, Pierre | Chauvet, Marie-Pierre | Azuar, Anne-Sophie | Rouzier, Roman | de Lara, Christine Tunon | Muracciole, Xavier | Agostini, Aubert | Gonçalves, Anthony | Lambaudie, Eric

Edité par CCSD ; Springer Verlag -

International audience. BACKGROUND:Tumour features associated with isolated invasive breast cancer (BC) ipsilateral local recurrence (ILR) after breast conservative treatment (BCT) and consequences on overall survival (OS) are still debated. Our objective was to investigate these points.METHODS:Patients were retrospectively identified from a cohort of patients who underwent BCT for invasive BC in 16 cancer centres. End-points were ILR rate and OS. The impact of ILR on OS was assessed by multivariate analysis (MVA) for all patients and according to endocrine receptors (ERs) and grade or tumour subtypes.RESULTS:Of 15,570 patients, ILR rate was 3.1%. Cumulative ILR rates differed according to ERs/grade (ERs+/Grade2: HR 1.42, p = 0.010; ERs+/Grade3: HR 1.41, p = 0.067; ERs-: HR 2.14, p < 0.0001), endocrine therapy (HR 2.05, p < 0.0001) and age < 40-years old (HR 2.28, p = 0.005) in MVA. When MVA was adjusted on tumour subtype, the latter was the only independent factor. OS-after-ILR was significantly different according to ILR-free intervals (HR 4.96 for ILR-free interval between 2 and 5-years and HR 9.00 when < 2-years, in comparison with ≥ 5-years).CONCLUSION:ERs/Grade status, lack of endocrine therapy and tumour subtypes predict isolated ILR risk in patients treated with BCT. Short ILR-free-intervals represent a strong pejorative factor for OS. These results may help selecting initial treatment as well as tailoring ILR systemic chemotherapy.

Consulter en ligne

Suggestions

Du même auteur

Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit

Archive ouverte | de Nonneville, Alexandre | CCSD

International audience. BACKGROUND:Invasive lobular carcinomas (ILCs) represent approximately 10% of all breast cancers. Despite this high frequency, benefit of adjuvant chemotherapy (CT) is still unclear.METHODS:Ou...

Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study

Archive ouverte | Houvenaeghel, Gilles | CCSD

International audience. Introduction: Few data have been reported regarding endocrine therapy (ET) in patients with small pT1a-b ER-postive breast cancer (BC). Thus, we conducted a study to detect possible survival ...

Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study

Archive ouverte | de Nonneville, Alexandre | CCSD

International audience

Chargement des enrichissements...